Compare Globus Medical Inc. Class A Common Stock (GMED) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.85 (market cap $10.25B), while Recursion Pharmaceuticals Inc trades at $3.73 (market cap $2.02B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 5.1× Recursion Pharmaceuticals Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GMED | RXRX | |
|---|---|---|
Market Cap | $10.25B | $2.02B |
Volume | 1,059,528 | 18,610,436 |
Sector | Health | Health |
52-Week High | $96.82 | $6.79 |
52-Week Low | $58.33 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $9.76B | $1.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after beating expectations in previous quarters. Financials show significant losses with -961.97% net income margin and $644.76M net loss in 2025, though revenue grew to $74.26M. Recent strategic partnerships with Tempus and Roche highlight AI-driven drug discovery focus.
Outlook remains speculative with high-risk/high-reward profile. The AI drug discovery platform shows promise through partnerships, but profitability challenges and cash burn require careful monitoring. Analyst consensus leans cautious with 40% buy ratings amid substantial operational losses. Key catalysts include pipeline advancements and partnership milestones through 2028.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
